Abstract: Compounds of the formula (I) wherein A, B, D, M, Ar, W, X, Y, Z and R1 are as defined herein, are useful in the prevention and treatment of hepatitis C infections. The compounds, their preparation, pharmaceutical compositions containing them and their use in medicine are disclosed.

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo-or radiosensitizers for cancer treatment.

Abstract: A navigation system has a display device for displaying a predefined maximal number of graphic driving lane objects. A control device is operatively configured such that the actual number of driving lanes of a street or road is determined, and only a maximal number of graphic driving lane objects is displayed on the display device when the maximal number is smaller than the actual number of driving lanes.

Abstract: Compounds of the formula (I): wherein A, B, D, M, Ar, W, X, Y, Z and R1 are as defined herein, are useful in the prevention and treatment of hepatitis C infections. The compounds, their preparation, pharmaceutical compositions containing them and their use in medicine are disclosed.

Abstract: Compounds of the formula (I): wherein A, B, D, M, Ar, W, X, Y, Z and R1 are as defined herein, are useful in the prevention and treatment of hepatitis C infections. The compounds, their preparation, pharmaceutical compositions containing them and their use in medicine are disclosed.

Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo-or radiosensitizers for cancer treatment.

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.

Abstract: A compound of the formula (I): as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing a compound of the formula (I) for use in inhibiting hepatitis C virus polymerase and/or of treating or preventing an illness due to hepatitis C virus,

Abstract: In the case of a method for the input of input data into a vehicle navigation device, by which input data are supplied to the vehicle navigation device by way of a receive interface and the input data are subjected to a plausibility check, in the event of a negative plausibility check, a prompt is emitted for correcting the input data. The input data can be corrected by a user via an operating device, and the corrected input data are imported into the vehicle navigation device.

Abstract: Compounds of the formula (I) wherein A, B, D, M, Ar, W, X, Y, Z and R1 are as defined herein, are useful in the prevention and treatment of hepatitis C infections. The compounds, their preparation, pharmaceutical compositions containing them and their use in medicine are disclosed.

Abstract: The present invention relates to macrocyclic compounds of formula (I): wherein W, n, m, R1, R2, R3, R4, R5, Ra, M, Z and ring B are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.

Abstract: A navigation system has a display device for displaying a predefined maximal number of graphic driving lane objects. A control device is operatively configured such that the actual number of driving lanes of a street or road is determined, and only a maximal number of graphic driving lane objects is displayed on the display device when the maximal number is smaller than the actual number of driving lanes.

Abstract: In the case of a system for marking a region within an image of a road map detail displayed on a vehicle video screen, the regions are shown in a circular shape. The center and the dimensions of the region can be changed by a control element, which can be rotated about a longitudinal axis and can be deflected transversely to the longitudinal axis. As a result of the transverse movement of the control element, the position of the center point and, as a result of the rotating movement of the control element, the dimensions of the region within the video screen, are adjustable.

Abstract: Disclosed are anhydrous transparent dispersions of polyurethane(meth)acrylate particles in a reactive diluent, which can be obtained by reacting a polyisocyanate with at least one polyol and a nucleophilically functionalized (meth)acrylic acid ester in the reactive diluent. The inventive dispersions are characterized in that the polyurethane(meth)acrylate particles have an average diameter of less than 40 nm. The invention further relates to a method for producing such dispersions, the use thereof as an adhesive, cast glass, or impact resistance modifier, and a molded article made from said dispersion.